EMS-Chemie stock holds firm as 2025 sales and profit metrics set the tone

EMS-Chemie (ISIN CH0016440353) sits on a 2025 revenue base of CHF 2.07 billion and net income of CHF 371 million, with operating cash flow of CHF 416 million supporting the balance sheet. The shares traded at CHF 653.00 as of 20 July 2026, giving the stock a current market reference alongside the latest reported figures.

CHF 2.07 billion sales

For 2025, EMS-Chemie reported sales of CHF 2.07 billion and EBITDA of CHF 610 million, while EBIT came in at CHF 564 million. The EBITDA margin therefore stood at 29.4%, a level that keeps the company in a high-margin peer group for specialty chemicals.

Net income of CHF 371 million for 2025 translated into a margin of 17.9% on sales, and operating cash flow of CHF 416 million covered most of the group’s earnings conversion needs. Those figures matter because they show that EMS-Chemie is still generating cash at a rate that supports dividends and investment without relying on external funding.

Margins still matter

EMS-Chemie also reported equity of CHF 1.75 billion at year-end 2025, with net cash and cash equivalents of CHF 435 million. Compared with the sales base of CHF 2.07 billion, that leaves the company with a conservative funding structure and limited leverage pressure.

The comparison that stands out is the relationship between revenue and profitability: CHF 610 million of EBITDA on CHF 2.07 billion of sales equals a margin just below 30%, while CHF 371 million of net income points to a very high conversion from operating profit to bottom-line earnings. For investors, that ratio is more useful than a simple top-line glance.

CHF 653 share level

The stock reference point is CHF 653.00 as of 20 July 2026, which places EMS-Chemie close enough to recent trading levels to keep valuation discussions grounded in current market data. The same date-based market marker is important because it ties the company’s 2025 report metrics to the trading price seen in mid-2026.

That combination of CHF 653.00 per share, CHF 2.07 billion in 2025 sales and CHF 371 million in net income provides the clearest picture available from the latest evidence set. The market is therefore valuing a business with high margins, cash generation and a strong capital base rather than a fast-growth story.

Performance mix

EMS-Chemie’s 2025 EBITDA of CHF 610 million and EBIT of CHF 564 million show that most of the earnings stack remains intact after operating costs. With operating cash flow at CHF 416 million, the company also kept cash generation ahead of many industrial peers in absolute terms.

The reported 2025 margin profile is the core takeaway: 29.4% EBITDA margin, 17.9% net margin and a CHF 435 million net cash position. Those numbers provide the investor context that usually matters most when the shares are trading without a dramatic catalyst.

Specialty products first

EMS-Chemie is best known for high-performance polymer solutions and specialty chemicals used in automotive, electronics and industrial applications. The product mix helps explain why the company can turn CHF 2.07 billion of sales into CHF 610 million of EBITDA and still preserve a net cash position.

For that reason, the product story is less about volume and more about mix, pricing power and margin discipline. A business that produced CHF 371 million of net income in 2025 has clearly kept that focus intact.

CHF 653.00 as of 20 July 2026

EMS-Chemie stock closed the latest market reference at CHF 653.00 as of 20 July 2026. That price sits beside the company’s 2025 reported figures and gives investors a simple way to connect market value with earnings quality.